Classifying cancers basedon T-cell infiltration and PD-L1

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2139-2145

  Teng, Michele W L ^a,b   Ngiow, Shin Foong ^a   Ribas, Antoni ^c,d   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; PROGRAMMED DEATH 1 LIGAND 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; CD274 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL DECISION MAKING; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; MELANOMA; NON INVASIVE PROCEDURE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; BIOSYNTHESIS; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84941797037     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0255     Document Type: Review

References (60)

1. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Vesely MD, Kershaw MH, Schreiber R.D., Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71.
3. Kroemer G, Galluzzi L, Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
4. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306.
5. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25: 261-7.
6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
7. Lewis CE, Pollard JW Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-12.
8. Bindea G, Mlecnik B, Tosolini M., Kirilovsky A, Waldner M, Obenauf Anna C, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-95.
9. Hodi FS, O'Day SJ, McDermott DF, Weber R.W., Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
10. Topalian SL, Hodi FS, Brahmer J.R., Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
11. Herbst RS, Soria JC, Kowanetz M, Fine G.D., Hamid O., Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
12. Powles T, Eder JP, Fine G.D., Braiteh FS, Loriot Y, Cruz C, et al MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-62.
13. Ansell SM, Lesokhin AM, Borrello I, Halwani A., Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-9.
14. Pardoll DM. The blockade of immune checkpoints in cancer immuno-therapy. Nat Rev Cancer 2012; 12: 252-64.
15. Taube JM, Anders RA, Young G.D., Xu H., Sharma R, McMiller TL, et al Colocalization of inflammatory response with B7-h1 expressioninhuman melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
16. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013; 19: 1021-34.
17. Brahmer JR, Tykodi SS, Chow L.Q., Hwu WJ, Topalian SL, Hwu P, et al Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
18. Hamid O, Robert C, Daud A., Hodi FS, Hwu WJ, Kefford R, et al Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-44.
19. O'Sullivan Coyne G, Madan RA, Gulley JL. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol 2014; 32: 986-88.
20. Topalian SL, Sznol M, McDermott D.F., Kluger HM, Carvajal RD, Sharfman WH, et al Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-30.
21. Parsa AT, Waldron JS, Panner A, Crane C.A., Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84-8.
22. Atefi M, Avramis E, Lassen A., Wong DJ, Robert L, Foulad D, et al Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20: 3446-57.
23. Taube JM, Klein AP, Brahmer J.R., Xu H., Pan X, Kim JH, et al Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-74.
24. Grosso J.H., Inzunza D, Cardona D., Simon J, Gupta A. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab. J Clin Oncol 31, 2013 (suppl; abstr 3016).
25. Ribas A, Tumeh PC The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res 2014; 20: 4982-4.
26. D'Incecco A., Andreozzi M, Ludovini V., Rossi E, Capodanno A, Landi L., et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015; 112: 95-102.
27. Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J., Velcheti V, Syrigos KN, et al Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 2015; 107.
28. Erdag G, Schaefer JT, Smolkin M.E., Deacon DH, Shea SM, Dengel LT, et al Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72: 1070-80.
29. Gandhi L BA, Hui R. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC)L Antitumor activity and association with tumor PD-L1 expression. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr CT105.
30. Daud Al H.O., Ribas A. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: Correlation of tumor PD-L1 expression with outcome[abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Abstract nr CT104.
31. Gerlinger M, Rowan AJ, Horswell S, Larkin J., Endesfelder D, Gronroos E, et al Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
32. Tumeh PC, Harview CL, Yearley J.H., Shintaku IP, Taylor EJ, Robert L, et al PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.
33. Matsushita H, Vesely MD, Koboldt D.C., Rickert CG, Uppaluri R, Magrini VJ, et al Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400-4.
34. Yadav M, Jhunjhunwala S, Phung Q.T., Lupardus P., Tanguay J, Bumbaca S, et al Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515: 572-6.
35. Guidoboni M, Gafa R, Viel A., Doglioni C, Russo A, Santini A., et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001; 159: 297-304.
36. Nosho K, Baba Y, Tanaka N., Shima K, Hayashi M, Meyerhardt J.A., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222: 350-66.
37. Chen DS, Irving BA, Hodi FS Molecular pathways: next-generation immu-notherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18: 6580-87.
38. Soria JC C.C., Bahleda R. Clinical activity, safety and biomarkers of PD-L1 blockade in non small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur Cancer Congr 2013; abstr 3408.
39. Brown SD, Warren RL, Gibb E.A., Martin SD, Spinelli JJ, Nelson BH, et al Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24: 743-50.
40. Gajewski TF, Woo SR, Zha Y, Spaapen R., Zheng Y, Corrales L, et al Cancer immunotherapy strategies based onovercoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25: 268-76.
41. Melero I, Rouzaut A, Motz G.T., Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immuno-therapy. Cancer Discov 2014; 4: 522-6.
42. Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol 2015; 33C: 55-63.
43. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607-15.
44. Crawford A, Angelosanto JM, Kao C, Doering T.A., Odorizzi PM, Barnett BE, et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 2014; 40: 289-302.
45. Page DB, Postow MA, Callahan M.K., Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014; 65: 185-202.
46. Intlekofer AM, Thompson CB At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013; 94: 25-39.
47. Rozali EN, Hato SV, Robinson B.W., Lake RA, Lesterhuis WJ. Programmed death ligand2 incancer-induced immune suppression. Clin Dev Immunol 2012; 2012: 656340.
48. Callahan MK, Wolchok JD At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013; 94: 41-53.
49. Ngiow SF, von Scheidt B, Akiba H, Yagita H., Teng MWL, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71: 3540-51.
50. Sakuishi K, Apetoh L, Sullivan J.M., Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathwaysto reverseTcellexhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-94.
51. Woo SR, Turnis ME, Goldberg M.V., Bankoti J., Selby M, Nirschl CJ, et al Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72: 917-27.
52. Johnston RJ, Comps-Agrar L, Hackney J., Yu X, Huseni M, Yang Y., et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26: 923-37.
53. Huang RR, Jalil J, Economou J.S., Chmielowski B., Koya RC, Mok S, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011; 17: 4101-9.
54. Wolchok JD, Kluger H, Callahan M.K., Postow MA, Rizvi NA, Lesokhin AM, et al Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
55. Bald T, Landsberg J, Lopez-Ramos D, Renn M., Glodde N, Jansen P, et al Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 2014; 4: 674-87.
56. Kershaw MH, Westwood JA, Darcy PK Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13: 525-41.
57. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest 2013; 123: 2756-63.
58. Ascierto PA, Kalos M, Schaer D.A., Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013; 19: 1009-20.
59. Mansfield JR, Hoyt C, Levenson RM Visualization of microscopy-based spectral imaging data from multi-label tissue sections. Curr Protoc Mol Biol 2008; Chapter 14: Unit 14 19.
60. Gerner MY, Kastenmuller W, Ifrim I., Kabat J, Germain RN. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. Immunity 2012; 37: 364-76.